Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: CNP520
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals